Dataset Information

The additional value of ¹⁸F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients.

ABSTRACT:

Objectives

Non-tuberculous mycobacteria (NTM) infection is an increasing health problem due to delaying an effective treatment. However, there are few data on ¹⁸F-FDG PET/CT for evaluating the status of NTM patients. The aim of this study was to investigate the potential value of ¹⁸F-FDG PET/CT in guiding the treatment strategy of NTM patients.

Methods

We retrospectively analyzed the cases of 23 NTM patients who underwent ¹⁸F-FDG PET/CT. The clinical data, including immune status and severity of NTM pulmonary disease (NTM-PD), were reviewed. The metabolic parameters of ¹⁸F-FDG included maximum standardized uptake value (SUV_max), SUV_max of the most FDG-avid lesion (SUV_Top), SUV_Top/SUV_max of the liver (SUR_Liver), SUV_Top/SUV_max of the blood (SUR_Blood), metabolic lesion volume (MLV), and total lesion glycolysis (TLG). The optimal cut-off values of these parameters were determined using receiver operating characteristic curves.

Results

There were 6 patients (26.09%) with localized pulmonary diseases and 17 patients (73.91%) with disseminated diseases. The NTM lesions had high or moderate ¹⁸F-FDG uptake (median SUV_Top: 8.2 ± 5.7). As for immune status, the median SUV_Top in immunocompromised and immunocompetent patients were 5.2 ± 2.5 and 10.0 ± 6.4, respectively, with a significant difference (P = 0.038). As for extent of lesion involvement, SUR_Liver and SUR_Blood in localized pulmonary and disseminated diseases were 1.9 ± 1.1 vs. 3.8 ± 1.6, and 2.7 ± 1.8 vs. 5.5 ± 2.6, respectively, with a significant difference (P = 0.016 and 0.026). Moreover, for disease severity, SUV_max of the lung lesion (SUV_I-lung) and SUV_max of the marrow (SUV_Marrow) in the severe group were 7.7 ± 4.3 and 4.4 ± 2.7, respectively, significantly higher than those in the non-severe group (4.4 ± 2.0 and 2.4 ± 0.8, respectively) (P = 0.027 and 0.036). The ROC curves showed that SUV_Top, SUR_Liver, SUR_Blood, SUV_I-lung, and SUV_Marrow had a high sensitivity and specificity for the identification of immune status, lesion extent, and severity of disease in NTM patients.

Conclusion

¹⁸F-FDG PET/CT is a useful tool in the diagnosis, evaluation of disease activity, immune status, and extent of lesion involvement in NTM patients, and can contribute to planning the appropriate treatment for NTM.

SUBMITTER: Chen D

PROVIDER: S-EPMC10949717 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The additional value of <sup>18</sup>F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients.

Chen Donghe D Chen Yunbo Y Yang Shuye S Liu Kanfeng K Wang Zhen Z Zhang Tingting T Wang Guolin G Zhao Kui K Su Xinhui X

Respiratory research 20240318 1

<h4>Objectives</h4>Non-tuberculous mycobacteria (NTM) infection is an increasing health problem due to delaying an effective treatment. However, there are few data on <sup>18</sup>F-FDG PET/CT for evaluating the status of NTM patients. The aim of this study was to investigate the potential value of <sup>18</sup>F-FDG PET/CT in guiding the treatment strategy of NTM patients.<h4>Methods</h4>We retrospectively analyzed the cases of 23 NTM patients who underwent <sup>18</sup>F-FDG PET/CT. The clinic ...[more]

PMID: 38500137

Similar Datasets

Project description:At present, 18F-fluorodesoxyglucose (18FDG) positron emission tomography (PET)/computed tomography (CT) cannot be used to omit a bone marrow biopsy (BMB) among initial staging procedures in follicular lymphoma (FL). The additional diagnostic value of skeletal textural features on baseline 18FDG-PET/CT in diffuse large B-cell lymphoma (DLBCL) patients has given promising results. The aim of this study is to evaluate the value of 18FDG-PET/CT radiomics for the diagnosis of bone marrow involvement (BMI) in FL patients. This retrospective bicentric study enrolled newly diagnosed FL patients addressed for baseline 18FDG PET/CT. For visual assessment, examinations were considered positive in cases of obvious bone focal uptakes. For textural analysis, the skeleton volumes of interest (VOIs) were automatically extracted from segmented CT images and analysed using LifeX software. BMB and visual assessment were taken as the gold standard: BMB -/PET - patients were considered as bone-NEGATIVE patients, whereas BMB +/PET -, BMB -/PET + and BMB +/PET + patients were considered bone-POSITIVE patients. A LASSO regression algorithm was used to select features of interest and to build a prediction model. Sixty-six consecutive patients were included: 36 bone-NEGATIVE (54.5%) and 30 bone-POSITIVE (45.5%). The LASSO regression found variance_GLCM, correlation_GLCM, joint entropy_GLCM and busyness_NGLDM to have nonzero regression coefficients. Based on ROC analysis, a cut-off equal to - 0.190 was found to be optimal for the diagnosis of BMI using PET pred.score. The corresponding sensitivity, specificity, PPV and NPV values were equal to 70.0%, 83.3%, 77.8% and 76.9%, respectively. When comparing the ROC AUCs with using BMB alone, visual PET assessment or PET pred.score, a significant difference was found between BMB versus visual PET assessments (p = 0.010) but not between BMB and PET pred.score assessments (p = 0.097). Skeleton texture analysis is worth exploring to improve the performance of 18FDG-PET/CT for the diagnosis of BMI at baseline in FL patients.

Project description:Knowledge of the within-subject variability of 18F-FDG PET/MRI measurements is necessary for proper interpretation of quantitative PET or MRI metrics in the context of therapeutic efficacy assessments with integrated PET/MRI scanners. The goal of this study was to determine the test-retest repeatability of these metrics on PET/MRI, with comparison to similar metrics acquired by PET/CT. Methods: This prospective study enrolled subjects with pathology-proven pelvic malignancies. Baseline imaging consisted of PET/CT immediately followed by PET/MRI, using a single 370-MBq 18F-FDG dose. Repeat imaging was performed within 7 d using an identical imaging protocol, with no oncologic therapy between sessions. PET imaging on both scanners consisted of a list-mode acquisition at a single pelvic station. The MRI consisted of 2-point Dixon imaging for attenuation correction, standard sequences for anatomic correlation, and diffusion-weighted imaging. PET data were statically reconstructed using various frame durations and minimizing uptake time differences between sessions. SUV metrics were extracted for both PET/CT and PET/MRI in each imaging session. Apparent diffusion coefficient (ADC) metrics were extracted for both PET/MRI sessions. Results: The study cohort consisted of 14 subjects (13 female, 1 male) with various pelvic cancers (11 cervical, 2 rectal, 1 endometrial). For SUVmax, the within-subject coefficient of variation (wCV) appeared higher for PET/CT (8.5%-12.8%) than PET/MRI (6.6%-8.7%) across all PET reconstructions, though with no significant repeatability differences (all P values ≥ 0.08) between modalities. For lean body mass-adjusted SUVpeak, the wCVs appeared similar for PET/CT (9.9%-11.5%) and PET/MRI (9.2%-11.3%) across all PET reconstructions, again with no significant repeatability differences (all P values ≥ 0.14) between modalities. For PET/MRI, the wCV for ADCmedian of 3.5% appeared lower than the wCVs for SUVmax (6.6%-8.7%) and SULpeak (9.2%-11.3%), though without significant repeatability differences (all P values ≥ 0.23). Conclusion: For solid tumors of the pelvis, the repeatability of the evaluated SUV and ADC metrics on 18F-FDG PET/MRI is both acceptably high and similar to previously published values for 18F-FDG PET/CT and MRI, supporting the use of 18F-FDG PET/MRI for quantitative oncologic treatment response assessments.

Dataset Information

The additional value of ¹⁸F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients.

Objectives

Methods

Results

Conclusion

Publications

The additional value of <sup>18</sup>F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

The additional value of 18F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients.

Objectives

Methods

Results

Conclusion

Publications

The additional value of <sup>18</sup>F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

The additional value of ¹⁸F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients.